Replacing TAF with other drugs did not affect weight, Swiss HIV Cohort reports.
Switching from tenofovir alafenamide (TAF) to the older formulation of tenofovir disoproxil (TDF) resulted in modest weight loss in people with HIV in the Swiss HIV Cohort, researchers report in the journal Clinical Infectious Diseases.
Switching from TAF to TDF also brought benefits in the forms of reduced cholesterol and triglycerides.
In contrast, switching from TAF-containing treatment to a two-drug combination of dolutegravir/lamivudine or injectable cabotegravir/rilpivirine did not lead to any changes in weight.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.